Investor Presentaiton

III Key Investment Highlights 5 Resilient Supply Chain Highly diversified supplier/client base significantly mitigating supply chain risks Geographic Concentration¹ Alexandria 11% Cairo & Canal 30% Alexandria 11% Cairo & Canal 44% Upper Egypt 19% % of Sales Upper Egypt 25% c.35k Clients Supplier Concentration¹ Sanofi Aventis 7% Amoun 5% Novartis 4% Pfizer 3% Mina Pharm % of Sales 3% SKUs Coverage¹ % of Market Sales Distributed by ISP 91% Delta 26% Delta 34% Low client concentration risk due to small number of pharmacy chains in Egypt Cairo & Canal region has the highest sales contribution due to higher purchasing power NOVARTIS gsk PHARMACEUTICALS Key Suppliers SANOFI Pfizer AstraZeneca PHARCO SERVIER PHARMACEUTICALS Others 79% Not Distributed by ISP 9% IN Minimal supplier concentration with the top five supplier representing less than 25% of sales Product portfolio covers 85% of the SKUs available in the market, collectively representing 91% of the market sales value SKU Concentration | # of SKUs per Revenue Decile Abbott Roche 6,596 ISP distributes over 9.5k SKUs with 20% of revenue generated from over 60 products which is in line with the market's SKUs distribution SEDICO ש سيديكو MINAPHARM AIKMA PHARMACEUTICALS QUALITY MUP Medical Union Pharmaceuticals GNP EIPICO AMOUN Marcyrl ibnsinapharma (1) As of Sep 2017 Source: IMS Health; Company Management 1,473 615 map 18 44 78 118 162 241 366 EVAPHARMA Bull-Apax Pharma Securing Your Health 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 15

View entire presentation